Calcitonin
Also known as: Miacalcin, Fortical, Salmon Calcitonin, sCT
Calcitonin is a naturally occurring hormone peptide that regulates calcium homeostasis and bone metabolism by inhibiting osteoclast activity and reducing bone resorption.
Calcitonin is a 3432 Da research peptide. Calcitonin is a naturally occurring hormone peptide that regulates calcium homeostasis and bone metabolism by inhibiting osteoclast activity and reducing bone resorption.
Also called: Miacalcin, Fortical, Salmon Calcitonin
3432
Molecular Weight
Daltons
4
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
4-8
Typical Dose
IU/kg
Overview
Calcitonin functions as a critical regulatory hormone in calcium and phosphate metabolism, primarily produced by the parafollicular cells of the thyroid gland. This 32-amino acid peptide exerts its effects by binding to calcitonin receptors on osteoclasts, leading to immediate inhibition of bone resorption activity. The synthetic salmon calcitonin variant demonstrates significantly higher potency than human calcitonin, making it the preferred form for research applications. Beyond bone metabolism, calcitonin influences renal calcium handling, gastrointestinal calcium absorption, and may provide analgesic effects in certain conditions. Research has examined calcitonin's potential in treating osteoporosis, Paget's disease, hypercalcemia, and various bone-related disorders. The peptide's rapid onset of action and specific mechanism make it valuable for studying calcium regulation pathways and bone remodeling processes.
Key Takeaways: Calcitonin
- Strongest evidence supports Calcitonin for bone resorption inhibition and hypercalcemia treatment
- Research doses typically range from 4 to 8 IU/kg via subcutaneous
- 4 benefits with strong evidence, 2 moderate, 1 preliminary
- Half-life: 10-15 minutes (IV), 23 minutes (subcutaneous)
- 4 cited research studies in this guide
Mechanism of Action
Calcitonin binds to G-protein coupled calcitonin receptors on osteoclasts, activating adenylyl cyclase and increasing intracellular cAMP levels. This signaling cascade rapidly inhibits osteoclast activity and motility, reducing bone resorption. The peptide also decreases renal tubular reabsorption of calcium and phosphate while inhibiting calcium absorption in the intestine. Additionally, calcitonin may activate analgesic pathways through central nervous system mechanisms, though these pathways remain less well characterized.
Research Benefits
Calcitonin at a Glance
Calcitonin binds to G-protein coupled calcitonin receptors on osteoclasts, activating adenylyl cyclase and increasing intracellular cAMP levels.
Bone Resorption Inhibition
Strong EvidenceRapidly suppresses osteoclast activity through cAMP-mediated signaling, leading to measurable decreases in bone turnover markers within hours of administration.
Hypercalcemia Treatment
Strong EvidenceEffectively lowers elevated serum calcium levels by reducing bone calcium release and increasing renal calcium excretion, particularly useful in malignancy-associated hypercalcemia.
Paget's Disease Control
Strong EvidenceNormalizes elevated alkaline phosphatase levels and reduces bone pain associated with Paget's disease through targeted inhibition of excessive bone turnover.
Calcium Homeostasis Regulation
Strong EvidenceMaintains calcium balance by coordinating bone, kidney, and intestinal calcium handling, preventing dangerous fluctuations in serum calcium levels.
Osteoporosis Management
Moderate EvidenceIncreases bone mineral density in postmenopausal women, particularly in the lumbar spine, though effects plateau after 1-2 years of treatment.
Analgesic Properties
Moderate EvidenceProvides pain relief in vertebral compression fractures and other bone-related pain conditions through mechanisms involving central pain pathways.
Fracture Healing Enhancement
PreliminaryMay accelerate bone healing processes by optimizing the balance between bone formation and resorption during repair phases.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Hypercalcemia research | 4–8 IU/kg | subcutaneous |
| Bone resorption studies | 50–100 IU | nasal |
| Osteoporosis research | 100–200 IU | nasal |
| Paget's disease studies | 50–100 IU | subcutaneous |
Frequency
Once daily to twice daily
Timing
Morning administration preferred for circadian alignment
Cycle Length
2-4 weeks for acute studies, 3-6 months for chronic research
Research Notes
- 1Nasal formulations require alternating nostrils daily
- 2Injectable forms may require refrigeration
- 3Calcium and vitamin D status should be optimized before treatment
- 4Response monitoring through bone turnover markers recommended
- 5Tachyphylaxis may develop with prolonged use
Reconstitution Guide
Standard Reconstitution
Vial Size
400 mg
Bacteriostatic Water
2 mL
Concentration
2000 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Calcitonin vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 2 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C. 2 years unopened, 28 days after reconstitution.
Storage Temperature
2-8°C
Shelf Life
2 years unopened, 28 days after reconstitution
Important Notes
- •Use sterile water for injection or bacteriostatic water
- •Gentle swirling preferred over vigorous shaking
- •Solution should be clear and colorless
- •Protect from light during storage
- •Single-use vials should not be shared between subjects
Calcitonin Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Calcitonin Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Nausea and vomiting (common with injectable forms)
- !Nasal irritation and rhinitis (nasal spray)
- !Flushing and warmth sensation
- !Injection site reactions and inflammation
- !Metallic taste
- !Diarrhea and abdominal cramping
- !Dizziness and headache
- !Hypocalcemia with excessive dosing
- !Allergic reactions (rare but serious)
- !Antibody development with long-term use
Potential Interactions
- ⚡Lithium may reduce calcitonin effectiveness
- ⚡Calcium supplements may counteract hypocalcemic effects
- ⚡Vitamin D analogs require dose adjustments
- ⚡Bisphosphonates may have additive bone effects
- ⚡Thiazide diuretics may enhance hypocalcemic risk
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Calcitonin in the treatment of acute hypercalcemia
Demonstrated rapid onset of hypocalcemic effects within 2-4 hours of calcitonin administration in patients with severe hypercalcemia.
Nasal calcitonin in postmenopausal osteoporosis
Large randomized trial showing 36% reduction in vertebral fracture risk with nasal calcitonin in postmenopausal women.
Calcitonin receptor signaling and bone remodeling
Detailed mechanistic study of calcitonin receptor activation and downstream signaling pathways in osteoclast regulation.
Salmon calcitonin in Paget's disease: long-term effects
Long-term study demonstrating sustained suppression of bone turnover markers and symptomatic improvement in Paget's disease patients.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Calcitonin begins lowering serum calcium within 2-4 hours of administration, with peak effects occurring at 6-8 hours. This rapid onset makes it valuable for acute hypercalcemic emergencies.
Salmon calcitonin is 40-50 times more potent than human calcitonin and has a longer duration of action. The synthetic salmon form is used in research due to its superior pharmacological properties.
While calcitonin can be used for extended periods, its effectiveness may diminish over time due to tachyphylaxis. Most research protocols limit continuous use to 6-12 months with monitoring breaks.
Yes, calcitonin formulations typically require storage at 2-8°C to maintain stability. Nasal sprays may be stored at room temperature for limited periods once opened.
Calcitonin overdose may cause severe hypocalcemia, manifesting as muscle cramps, tetany, seizures, or cardiac arrhythmias. Immediate medical attention and calcium supplementation are required.
Research typically monitors serum calcium, phosphate, and bone turnover markers like CTX and P1NP. Alkaline phosphatase levels are particularly useful in Paget's disease studies.
Calcitonin does not cause physical dependency, but prolonged use may lead to reduced effectiveness. Research protocols often include treatment holidays to restore sensitivity.
Calcitonin requires dose adjustment in renal impairment since the kidneys play a role in its elimination. Close monitoring of calcium and phosphate levels is essential in these populations.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.